4CPS-072 Real-world experience in haemophilia B patients after switching to fix extended half-life using pharmacokinetic population software and monocompartmental model

Background and ImportanceNew strategies have been developed for the prophylactic treatment of patients with haemophilia B (HB) such as extended half-life recombinant factor IX concentrates (rFIX EHL). These products have shown favourable pharmacokinetic properties, attaining a half-life 3- to 5-fold...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A47-A48
Hauptverfasser: Juárez-Giménez, JC, Benítez-Hidalgo, O, Romero-Garrido, JA, Mateos-Salillas, C, González-Piñeiro, S, Montoro-Ronsano, JB
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!